Navigation Links
DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
Date:1/5/2012

CUPERTINO, Calif., Jan. 5, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial).  POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER™ technology to deliver bupivacaine and is designed to provide up to three days of pain relief after surgery.  BESST was conducted to measure the safety and efficacy of POSIDUR versus placebo in one abdominal surgical procedure and versus an active comparator (injections of standard bupivacaine) in two other abdominal surgical procedures. The co-primary endpoints were pain intensity as well as the use of opioid analgesics over the first 3 days following surgery.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

While the results trended positive for both pain reduction and reduction of supplemental opioid use in the first three days after surgery, they did not reach statistical significance.  There were no signs of systemic safety issues, although local site reactions were observed more frequently in the POSIDUR and SABER-Placebo groups than in the active comparator groups. A full safety assessment is not yet available. 

"POSIDUR continues to appear to be safe based on our preliminary review of the BESST data, which also suggests a reduction in pain associated with surgical incision in all three cohorts," stated James E. Brown, President and CEO.  "After a complete analysis of the BESST data and preparation of integrated safety and efficacy reports combining our previous well controlled studies, we intend to hold a pre-NDA meeting with the FDA."

"Hospira looks forward to DURECT's conversations with the FDA, and we su
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
2. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
3. DURECT Corporation to Participate in Upcoming Healthcare Conferences
4. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
5. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
6. DURECT to Present at the Jefferies Healthcare Conference
7. DURECT Announces Resignation of Chief Medical Officer
8. DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
9. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
10. DURECT to Present at Cowen and Company Health Care Conference
11. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... MicroDose Technologies,Inc. (MicroDose) today announced that the first ... Inc., through a Merck affiliate, has been,achieved, triggering ... MicroDose,s dry powder inhaler (DPI) technology announced in ... of a Phase I clinical,study of an investigational ...
... -Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular ... ... SUNNYVALE, Calif., Aug. 5 Icon Bioscience, Inc., (IBI),a privately ... its Phase I clinical trial to assess the,safety and efficacy of ...
Cached Medicine Technology:MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. 2Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate 2
(Date:4/24/2014)... 28, the Center for BrainHealth will bring together ... pressing brain-related challenges at its inaugural Brain Health ... Regeneration." Featured speakers will include Dr. Sandra Bond ... for BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. ... Assistant Secretary for Policy and Early Learning, U.S. ...
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... the worldwide leader of post-breast surgery products, ... Collection, the industry,s first post-surgical garments infused ... discomfort after breast surgery.(Logo: ... http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 )The post-surgical camisole and ...
... NORTH BRUNSWICK¿ N.J.¿ April 8 ORTHOCON¿ Inc. today ... company as President and Chief Executive Officer. The company ... of financing led by top-tier healthcare investors. ORTHOCON ... bone. The Company,s versatile technology platform may be leveraged ...
... for good nutrition but lack knowledge of food prep ... the current economic conditions, three-quarters of what people eat ... dependent on what food families keep in their kitchens. ... freezers, Rutgers University researchers found that, in ...
... Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today ... (BGM) in its Phase 2 clinical safety trial with ... BGM will measure levels of Galectin-3 in patients enrolled ... remodeling associated with advanced stages of heart failure. CDP-1050 ...
... NORTHFIELD, Ill., April 8 The College of American ... accreditation organization and deeming authority under the Clinical Laboratory ... and Medicaid Services (CMS) since 1995, has been notified ... subspecialties for a six-year period, the longest period available ...
... LAS VEGAS, April 8 Scheduled for June 5 ... garnered broad industry support and surpassed previous levels of ... this annual medical education and commercial exhibition event has ... a focal point for the high-growth medical aesthetic industry. ...
Cached Medicine News:Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 2Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 4Health News:CAP Deeming Status Renewed 2Health News:THE Aesthetic Show Attracts Record Sponsorship 2Health News:THE Aesthetic Show Attracts Record Sponsorship 3
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: